Androgen Decline and Survival During Docetaxel Therapy in metastatic Castration Resistant Prostate Cancer (mCRPC)

BACKGROUND: Multiple androgens drive prostate cancer progression and higher pre-treatment levels of androgens, even within the castrate range, have been previously shown to be associated with an improved overall survival (OS) in mCRPC. Docetaxel impairs microtubules, has androgen receptor (AR) inhib...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Prostate Cancer Prostatic Dis
Autori principali: Ryan, Charles J, Dutta, Sandipan, Kelly, William K, Russell, Carly, Small, Eric J., Morris, Michael J., Taplin, Mary-Ellen, Halabi, Susan
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2019
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6825875/
https://ncbi.nlm.nih.gov/pubmed/31053766
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41391-019-0152-3
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi